Table of Contents Author Guidelines Submit a Manuscript
Advances in Virology
Volume 2015, Article ID 687162, 9 pages
http://dx.doi.org/10.1155/2015/687162
Research Article

Nelfinavir Impairs Glycosylation of Herpes Simplex Virus 1 Envelope Proteins and Blocks Virus Maturation

1Seattle Children’s Research Institute, University of Washington, Seattle, WA 98101, USA
2Department of Pediatrics, University of Washington, Seattle, WA 98105, USA
3Department of Global Health, University of Washington, Seattle, WA 98195, USA
4Department of Microbiology, University of Washington, Seattle, WA 98195, USA
5Department of Medicine, University of Washington, Seattle, WA 98195, USA
6Department of Epidemiology, University of Washington, Seattle, WA 98195, USA
7Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Received 7 October 2014; Revised 8 January 2015; Accepted 12 January 2015

Academic Editor: Gary S. Hayward

Copyright © 2015 Soren Gantt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents, “Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,” September 2014, http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
  2. R. H. Gray, M. J. Wawer, R. Brookmeyer et al., “Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda,” The Lancet, vol. 357, no. 9263, pp. 1149–1153, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. Adolescents PoAGfAa, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services, 2013.
  5. N. Ford, Z. Shubber, P. Saranchuk et al., “Burden of HIV-Related cytomegalovirus retinitis in resource-limited settings: a systematic review,” Clinical Infectious Diseases, vol. 57, no. 9, pp. 1351–1361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Posavad, A. Wald, S. Kuntz et al., “Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 190, no. 4, pp. 693–696, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Lodi, M. Guiguet, D. Costagliola, M. Fisher, A. de Luca, and K. Porter, “Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion,” Journal of the National Cancer Institute, vol. 102, no. 11, pp. 784–792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. E. de Clercq, “A cutting-edge view on the current state of antiviral drug development,” Medicinal Research Reviews, vol. 33, no. 6, pp. 1249–1277, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Gantt, J. Carlsson, M. Ikoma et al., “The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 6, pp. 2696–2703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. W. A. Chow, C. Jiang, and M. Guan, “Anti-HIV drugs for cancer therapeutics: back to the future?” The Lancet Oncology, vol. 10, no. 1, pp. 61–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Gantt, C. Casper, and R. F. Ambinder, “Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention,” Current Opinion in Oncology, vol. 25, no. 5, pp. 495–502, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. B. Brunner, M. Geiger, G. G. Grabenbauer et al., “Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 26, no. 16, pp. 2699–2706, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Buijsen, G. Lammering, R. L. H. Jansen et al., “Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer,” Radiotherapy and Oncology, vol. 107, no. 2, pp. 184–188, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Rengan, R. Mick, D. Pryma et al., “A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response,” Journal of Thoracic Oncology, vol. 7, no. 4, pp. 709–715, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Pan, M. Mott, B. Xi et al., “Phase I study of nelfinavir in liposarcoma,” Cancer Chemotherapy and Pharmacology, vol. 70, no. 6, pp. 791–799, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. J. J. Gills, J. LoPiccolo, and P. A. Dennis, “Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy,” Autophagy, vol. 4, no. 1, pp. 107–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Xie, T. Evangelidis, and P. E. Bourne, “Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir,” PLoS Computational Biology, vol. 7, no. 4, Article ID e1002037, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Y. Liu and B. Roizman, “The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate,” Journal of Virology, vol. 65, no. 10, pp. 5149–5156, 1991. View at Google Scholar · View at Scopus
  19. M. J. Karnovsk, “A formaldehyde-glutaraldehyde fixative of high osmolality for use in electron microscopy,” Journal of Cell Biology, vol. 27, pp. A137–A138, 1965. View at Google Scholar
  20. L. E. Schnipper and C. S. Crumpacker, “Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 4, pp. 2270–2273, 1980. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Gills, J. LoPiccolo, J. Tsurutani et al., “Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo,” Clinical Cancer Research, vol. 13, no. 17, pp. 5183–5194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Petrich, V. Leshchenko, P.-Y. Kuo et al., “Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma,” Clinical Cancer Research, vol. 18, no. 9, pp. 2534–2544, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Kraus, J. Bader, H. Overkleeft, and C. Driessen, “Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance,” Blood Cancer Journal, vol. 3, no. 3, article e103, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M.-J. Hsu, C.-Y. Wu, H.-H. Chiang, Y.-L. Lai, and S.-L. Hung, “PI3K/Akt signaling mediated apoptosis blockage and viral gene expression in oral epithelial cells during herpes simplex virus infection,” Virus Research, vol. 153, no. 1, pp. 36–43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. N. N. Kalu, P. J. Desai, C. M. Shirley, W. Gibson, P. A. Dennis, and R. F. Ambinder, “Nelfinavir inhibits maturation and export of herpes simplex virus 1,” Journal of Virology, vol. 88, no. 10, pp. 5455–5461, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Guan, K. Fousek, and W. A. Chow, “Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer,” The FEBS Journal, vol. 279, no. 13, pp. 2399–2411, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Mahoney, K. Maddocks, J. Flynn et al., “Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies,” Leukemia & Lymphoma, vol. 54, no. 12, pp. 2685–2692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Thomas, N. Sharma, E. B. Golden et al., “Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors,” Cancer Letters, vol. 325, no. 1, pp. 63–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Brüning, P. Burger, M. Vogel et al., “Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis,” Cancer Biology and Therapy, vol. 8, no. 3, pp. 222–228, 2009. View at Google Scholar · View at Scopus
  30. D. C. Johnson and P. G. Spear, “O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus,” Cell, vol. 32, no. 3, pp. 987–997, 1983. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Chatterjee, S. Nishimuro, and R. J. Whitley, “Expression of HSV-1 glycoproteins in tunicamycin-treated monkey kidney cells,” Biochemical and Biophysical Research Communications, vol. 167, no. 3, pp. 1139–1145, 1990. View at Publisher · View at Google Scholar · View at Scopus
  32. C. E. Isaacs, W. Xu, R. K. Pullarkat, and R. Kascsak, “Retinoic acid reduces the yield of herpes simplex virus in Vero cells and alters the N-glycosylation of viral envelope proteins,” Antiviral Research, vol. 47, no. 1, pp. 29–40, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. M. E. Taylor and K. Drickamer, Introduction to Glycobiology, Oxford University Press, Oxford, UK, 2011.
  34. A. Varki, “NCBI bookshelf,” in Essentials of Glycobiology, p. 1, Cold Spring Harbor Laboratory Press, New York, NY, USA, 2nd edition, 2009. View at Google Scholar
  35. N. Yamamoto, R. Yang, Y. Yoshinaka et al., “HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus,” Biochemical and Biophysical Research Communications, vol. 318, no. 3, pp. 719–725, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Federico, “HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step,” Virology, vol. 417, no. 1, pp. 37–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. F. N. Linero, C. S. Sepúlveda, F. Giovannoni et al., “Host cell factors as antiviral targets in arenavirus infection,” Viruses, vol. 4, no. 9, pp. 1569–1591, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Coley, K. Kehn-Hall, R. van Duyne, and F. Kashanchi, “Novel HIV-1 therapeutics through targeting altered host cell pathways,” Expert Opinion on Biological Therapy, vol. 9, no. 11, pp. 1369–1382, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. A. Khattab, “Targeting host factors: a novel rationale for the management of hepatitis C virus,” World Journal of Gastroenterology, vol. 15, no. 28, pp. 3472–3479, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. S. A. Krumm, J. M. Ndungu, J.-J. Yoon et al., “Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases,” PLoS ONE, vol. 6, no. 5, Article ID e20069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Pastorino, A. Nougairède, N. Wurtz, E. Gould, and X. de Lamballerie, “Role of host cell factors in flavivirus infection: implications for pathogenesis and development of antiviral drugs,” Antiviral Research, vol. 87, no. 3, pp. 281–294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Brüning, A. Gingelmaier, K. Friese, and I. Mylonas, “New prospects for nelfinavir in non-HIV-related diseases,” Current Molecular Pharmacology, vol. 3, no. 2, pp. 91–97, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Pyrko, A. Kardosh, W. Wang, W. Xiong, A. H. Schönthal, and T. C. Chen, “HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress,” Cancer Research, vol. 67, no. 22, pp. 10920–10928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. L. I. Pizer, G. H. Cohen, and R. J. Eisenberg, “Effect of tunicamycin on herpes simplex virus glycoproteins and infectious virus production,” Journal of Virology, vol. 34, no. 1, pp. 142–153, 1980. View at Google Scholar · View at Scopus
  45. E. Katz, E. Margalith, and D. Duksin, “Antiviral activity of tunicamycin on herpes simplex virus,” Antimicrobial Agents and Chemotherapy, vol. 17, no. 6, pp. 1014–1022, 1980. View at Publisher · View at Google Scholar · View at Scopus
  46. K. G. Kousoulas, D. J. Bzik, N. Deluca, and S. Person, “The effect of ammonium chloride and tunicamycin on the glycoprotein content and infectivity of herpes simplex virus type 1,” Virology, vol. 125, no. 2, pp. 468–474, 1983. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Campadelli-Fiume, L. Poletti, F. Dall'Olio, and F. Serafini-Cessi, “Infectivity and glycoprotein processing of herpes simplex virus type 1 grown in a ricin-resistant cell line deficient in N-acetylglucosaminyl transferase I,” Journal of Virology, vol. 43, no. 3, pp. 1061–1071, 1982. View at Google Scholar · View at Scopus
  48. G. S. Taylor, J. Mautner, and C. Münz, “Autophagy in herpesvirus immune control and immune escape,” Herpesviridae, vol. 2, article 2, 2011. View at Publisher · View at Google Scholar
  49. V. le Sage and B. W. Banfield, “Dysregulation of autophagy in murine fibroblasts resistant to HSV-1 infection,” PLoS ONE, vol. 7, no. 8, Article ID e42636, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Pei, Z.-P. Chen, H.-Q. Ju et al., “Autophagy is involved in anti-viral activity of pentagalloylglucose (PGG) against Herpes simplex virus type 1 infection in vitro,” Biochemical and Biophysical Research Communications, vol. 405, no. 2, pp. 186–191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. D. J. Klionsky, H. Abeliovich, P. Agostinis et al., “Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes,” Autophagy, vol. 4, no. 2, pp. 151–175, 2008. View at Publisher · View at Google Scholar
  52. W. Wu, R. Zhang, and D. R. Salahub, “Nelfinavir: a magic bullet to annihilate cancer cells?” Cancer Biology and Therapy, vol. 8, pp. 233–235, 2009. View at Google Scholar · View at Scopus